Evidence map›Paper›PMID 34406412›Full record

ArticleJournal of cell science2021

Induction of apically mistrafficked epiregulin disrupts epithelial polarity via aberrant EGFR signaling.

Bhuminder Singh, Galina Bogatcheva, Evan Krystofiak, Eliot T McKinley, Salisha Hill, Kristie Lindsey Rose, James N Higginbotham, Robert J Coffey

Open access · bronzeAbstract read
In one paragraph

Article in Journal of cell science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Bhuminder SinghDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0003-1357-2158
Galina BogatchevaDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Evan KrystofiakCell Imaging Shared Resource, Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Eliot T McKinleyDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Salisha HillDepartment of Biochemistry, Vanderbilt University, Nashville, TN 37232, USA.ORCID 0000-0002-4145-969X
Kristie Lindsey RoseDepartment of Biochemistry, Vanderbilt University, Nashville, TN 37232, USA.
James N HigginbothamDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Robert J CoffeyDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0002-2180-3844
Vanderbilt University Medical Center · USVanderbilt University · US

Funding

Understanding and Controlling p120 Dysfunction in CRCP50CA095103 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI COFFEY, ROBERT J. · 2002 to 2017
$33.6M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal CancerP50CA236733 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Robert J. Coffey · 2019 to 2026
$19.6M
Integrated approach to study early and late events in colonic neoplasia: mouse to manR35CA197570 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Robert J. Coffey · 2017 to 2026
$9.4M
Institutional Career Development CoreKL2TR002245 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Julie A. Bastarache · 2017 to 2026
$9.3M
Role of Receptor Tyrosine Kinase cross-talk in colorectal cancerR01CA248505 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SINGH, BHUMINDER · 2021 to 2025
$2.2M
NCATS NIH HHS KL2 TR002245NCATS NIH HHS KL2TR002245NCI NIH HHS P50 CA095103NCI NIH HHS P50 CA236733NCI NIH HHS R01 CA248505NCI NIH HHS R35 CA197570NIDDK NIH HHS P30 DK058404
6 · The paper itself

Abstract

In polarized MDCK cells, disruption of the tyrosine-based YXXΦ basolateral trafficking motif (Y156A) in the epidermal growth factor receptor (EGFR) ligand epiregulin (EREG), results in its apical mistrafficking and transformation in vivo. However, the mechanisms underlying these dramatic effects are unknown. Using a doxycycline-inducible system in 3D Matrigel cultures, we now show that induction of Y156A EREG in fully formed MDCK cysts results in direct and complete delivery of mutant EREG to the apical cell surface. Within 3 days of induction, ectopic lumens were detected in mutant, but not wild-type, EREG-expressing cysts. Of note, these structures resembled histological features found in subcutaneous xenografts of mutant EREG-expressing MDCK cells. These ectopic lumens formed de novo rather than budding from the central lumen and depended on metalloprotease-mediated cleavage of EREG and subsequent EGFR activity. Moreover, the most frequent EREG mutation in human cancer (R147stop) resulted in its apical mistrafficking in engineered MDCK cells. Thus, induction of EREG apical mistrafficking is sufficient to disrupt selective aspects of polarity of a preformed polarized epithelium. This article has an associated First Person interview with the first author of the paper.

Indexed as

ErbB ReceptorsSignal TransductionEpiregulinHumansIntercellular Signaling Peptides and ProteinsPhosphorylationEGFR protein, humanEpiregulinErbB ReceptorsIntercellular Signaling Peptides and Proteins3D Matrigel cultureEGFREpidermal growth factor receptorEpiregulinEpithelial polarityEpithelial transformationEREGProtein trafficking

Identifiers

PMID34406412
PMCPMC8466005
OpenAlexW3194884646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.